Charles Schwab Investment Management Inc. Boosts Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Charles Schwab Investment Management Inc. raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 1.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 465,620 shares of the biopharmaceutical company’s stock after acquiring an additional 8,093 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.82% of Agios Pharmaceuticals worth $20,687,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth $37,000. Quest Partners LLC purchased a new stake in Agios Pharmaceuticals in the second quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 363 shares in the last quarter. CWM LLC grew its stake in shares of Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 1,836 shares during the last quarter. Finally, North Star Asset Management Inc. acquired a new position in shares of Agios Pharmaceuticals during the second quarter valued at about $216,000.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.93% of the stock is owned by company insiders.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $61.64 on Friday. The company has a market capitalization of $3.52 billion, a P/E ratio of 5.43 and a beta of 0.80. The business’s 50-day moving average is $49.93 and its two-hundred day moving average is $46.28. Agios Pharmaceuticals, Inc. has a fifty-two week low of $20.96 and a fifty-two week high of $62.58.

Analyst Ratings Changes

AGIO has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Scotiabank upped their target price on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. Raymond James reaffirmed an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Finally, Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $52.33.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.